Results of an abbreviated Phase Ib study of the HDAC6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer

Peripheral neuropathy is a common side effect of chemotherapeutic agents that frequently necessitates dose-reduction, truncation of, or change in therapy. HDAC6 inhibition has demonstrated preclinical efficacy in preventing and/or reversing chemotherapy-induced peripheral neuropathy and furthermore...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Elizabeth K., Tan-Wasielewski, Zhenying, Matulonis, Ursula A., Birrer, Michael J., Wright, Alexi A., Horowitz, Neil, Konstantinopoulos, Panagiotis A., Curtis, Jennifer, Liu, Joyce F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6712364/
https://www.ncbi.nlm.nih.gov/pubmed/31467965
http://dx.doi.org/10.1016/j.gore.2019.07.010
Descripción
Sumario:Peripheral neuropathy is a common side effect of chemotherapeutic agents that frequently necessitates dose-reduction, truncation of, or change in therapy. HDAC6 inhibition has demonstrated preclinical efficacy in preventing and/or reversing chemotherapy-induced peripheral neuropathy and furthermore has demonstrated synergistic antitumor activity with various chemotherapies. Here, we report the abbreviated results of a Phase Ib trial of ricolinostat, an HDAC6-specific inhibitor, in combination with paclitaxel, in the treatment of recurrent ovarian, fallopian tube, or primary peritoneal cancer.

Ejemplares similares